• EuBiologics applied to South Korea’s MFDS on Sept. 18, 2026, for Phase 2 trial authorization for its EuHZV shingles vaccine.
• The trial will enroll 150 healthy adults aged 50 or older to compare the vaccine’s immune response with Shingrix.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. EuBiologics Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261021900649), on October 21, 2026, and is solely responsible for the information contained therein.